As of June 30, 2025, MEI Pharma, Inc. has 6.66M shares outstanding.
| Shares Outstanding | 6.66M |
These figures are as of June 30, 2025.
| PB Ratio | -0.04 |
| P/TBV Ratio | 0.97 |
| P/FCF Ratio | -0.79 |
| P/OCF Ratio | -0.79 |
As of June 30, 2025, MEI Pharma, Inc. maintains a current ratio of 13.50, meaning it holds 13.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 13.50 |
| Quick Ratio | 13.30 |
These figures cover the twelve months ended June 30, 2025. Return on assets (ROA) is negative at -53.45, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -53.45 |
As of the close on October 6, 2025, MEI Pharma, Inc.'s stock has declined approximately 7.47% over the past 52 weeks. The 50-day moving average sits at 4.00, while the 200-day moving average is 2.94.
| 52-Week Price Change | -7.47% |
| 50-Day Moving Average | 4.00 |
| 200-Day Moving Average | 2.94 |
These figures cover the twelve months ended June 30, 2025. Free cash flow yield is negative at -126.65: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.
| FCF Yield | -126.65 |
MEI Pharma, Inc.'s most recent stock split took place on April 17, 2023 with a 20:1 split ratio.
| Last Split Date | 4/17/2023 |
| Split Ratio | 20:1 |
As of June 30, 2025, MEI Pharma, Inc. has an Altman Z-Score of -25.69, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -25.69 |